<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351270</url>
  </required_header>
  <id_info>
    <org_study_id>NatHis-CNM</org_study_id>
    <nct_id>NCT03351270</nct_id>
  </id_info>
  <brief_title>Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies</brief_title>
  <acronym>NatHis-CNM</acronym>
  <official_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynacure</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Myologie, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the 2 years extension of the European part of the prospective and longitudinal study
      of the natural history and function of patients with myotubular myopathy (MTM) initially
      sponsored by Valerion therapeutics. Twenty additional patients with other centronuclear
      myopathies (CNM) (due to mutation in MTM1 but also in DNM2 or BIN1 genes) are planned to be
      enrolled in one year leading to an expected total number of 60 patients followed at least
      over 1 year period. Data from the study will be used to characterize the disease course of
      CNM and determine which outcome measures will be the best to assess the efficacy of potential
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MFM score change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>Motor Function Measure scale. The total test score can range from 0 if the subject cannot perform any of the items to 100 if all the items are fully achieved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHOP-INTEND score change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Hammersmith score change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>Modified Hammersmith Functional Motor Scale. The total test score can range from 0 if the subject cannot perform any of the items to 40 if all the items are fully achieved</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Moviplate score change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>Moviplate score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6MWD change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>6 Minute Walking Distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grip strength change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>MyoGrip</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pinch strength change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
    <description>MyoPinch</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Vital Capacity change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Cough Flow change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Inspiratory Pressure change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Expiratory Pressure change from baseline</measure>
    <time_frame>Baseline, 6 months, 12 months and every year up to 60 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Centronuclear Myopathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized strength, respiratory and motor function assessments</intervention_name>
    <description>Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any age (newborns included) may participate

          -  Patients over 18 years of age and parent(s)/legal guardian(s) of patients &lt; 18 years
             of age must be provide written informed consent prior to participating in the study
             and informed assent will be obtained from minors at least 7 years of age when required
             by regulation.

          -  Myotubular Centronuclear myopathy (MTMCNM) resulting from a mutation in the MTM1, DNM2
             or BIN1 gene

          -  Male or symptomatic female. A symptomatic female will be defined by the motor function
             assessment by Motor Function Measure (MFM) or North Star Ambulatory Assessment (NSAA)
             below 80% of the total score.

          -  Willing and able to comply with all protocol requirements and procedures.

          -  In France only: Affiliated to or a beneficiary of a social security category

        Exclusion Criteria:

          -  Other disease which may significantly interfere with the assessment of the MTM CNM and
             is clearly not related to the disease

          -  Currently enrolled in a treatment study; or treatment with an experimental therapy
             other than pyridostigmine

          -  For women: pregnancy or current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Servais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Institut de Myologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Servais, MD</last_name>
    <phone>+33 1 44 73 65 44</phone>
    <email>l.servais@institut-myologie.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence neuromusculaire, CHR La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore Daron, MD</last_name>
      <email>aurore.daron@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant, CHU Lyon L'Escale</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Vuillerot, MD</last_name>
      <email>carole.vuillerot@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Cuisset, MD</last_name>
      <email>Jean-Marie.CUISSET@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mayer, MD</last_name>
      <email>lobo.mayer@trs.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>I-Motion Institute - Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Annoussamy, PhD</last_name>
      <email>m.annoussamy@institut-myologie.org</email>
    </contact>
    <contact_backup>
      <last_name>Virginie Chê</last_name>
      <email>v.che@institut-myologie.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Myology</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Annoussamy, PhD</last_name>
      <email>m.annoussamy@institut-myologie.org</email>
    </contact>
    <contact_backup>
      <last_name>Virginie Chê</last_name>
      <email>v.che@institut-myologie.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Arnal, MD</last_name>
      <email>Jean-Michel.Arnal@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR)</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schara, MD</last_name>
      <email>ulrike.schara@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Children's Hospital</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adele D'Amico, MD</last_name>
      <email>adele2.damico@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>21-11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Hernandez</last_name>
      <email>artucadiz@ono.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNM</keyword>
  <keyword>XLMTM</keyword>
  <keyword>Myotubular myopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

